Organization
Medical Univ of Vienna, Vienna, Austria
2 abstracts
Abstract
BIOLOGIC FREE DISEASE CONTROL (BFDC) IN EARLY RA: PREDICTORS OF SUCCESSFUL WITHDRAWAL OF ADALIMUMAB (ADA) AFTER ACHIEVING STABLE LOW DISEASE ACTIVITY WITH ADA PLUS METHOTREXATE (MTX) – DATA FROM THE OPTIMA STUDY Org: Medical Univ of Vienna, Vienna, Austria, Leeds Teaching Hospital, Leeds, United Kingdom, U of Texas Southwestern Med Center, Dallas, United States, Karolinska Univ Hospital, Stockholm, Sweden, Abbott, Abbott Park, United States,
Abstract
BARICITINIB-ASSOCIATED CHANGES IN GLOBAL GENE EXPRESSION DURING A 24-WEEK PHASE 2 CLINICAL SLE TRIAL DESCRIBE A MECHANISM OF ACTION THROUGH INHIBITION OF JAK/STAT AND IFN RESPONSIVE GENE EXPRESSIONOrg: Charite Universitätsmedizin Berlin and Deutsches Rheumaforschungszentrum (DRFZ), Berlin, Germany, Univ of Occupational and Environmental Health, Kitakyushu, Japan, Johns Hopkins Univ School of Medicine, Baltimore, United States of America, Medical Univ of Vienna, Vienna, Austria, Eli Lilly and Company, Indianapolis, United States of America,